Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 1,182

Document Document Title
WO/2022/150924A1
Carbohydrate of Formula (A) where R1 is H and n an integer from 1 to 5, is synthesized by reacting, under heating, compound (A0) with HO-(CH2)n-CH=CH2 in the presence of an acid capable of liberating a proton, and cooling the reaction mi...  
WO/2022/155289A1
This disclosure relates to PEGylated selectin inhibitors, compositions, and methods related thereto. In certain embodiments, the disclosure relates to glycopeptides that contain one or more modified amino acids conjugated to a saccharide...  
WO/2022/148816A1
This invention relates to the inhibition of the proliferation and/or activation of T cells by full-length factor V (FV) protein and peptides derived from full-length FV protein. This may be used to exert an immunosuppressive effect in th...  
WO/2022/148868A1
An optimized method for synthesizing dalbavancin is provided in which an organic antisolvent such as tert-butyl methyl ether (TBME) or dimethoxyethane (DME) is used to precipitate the product of the esterification of A-40926.  
WO/2022/119917A1
The present invention provides compositions and methods useful in the diagnosis and treatment of a variety of cognitive impairments including vascular cognitive impairment and dementia, and Alzheimer's Disease. In one particular embodime...  
WO/2022/109327A1
Methods for measuring disialylated Fc glycan in a biological sample are described.  
WO/2022/093684A1
It has been discovered that phosphorylation-dependent uncoupling of endothelial nitric oxide synthase (eNOS) plays an important role in endothelial cell (EC) barrier disruption. Compositions and methods to reduce or prevent eNOS uncoupli...  
WO/2022/037665A1
The present disclosure provides a site-specific protein conjugate and the method for preparation of the same. The protein conjugate comprising a protein and an oligosaccharide, wherein said oligosaccharide comprises (I) wherein: said Glc...  
WO/2021/228853A1
The present invention relates to a vaccine composition and its use against a Severe acute respiratory syndrome-related coronavirus.  
WO/2021/216323A1
A series of vancomycin C-terminus guanidine modifications are disclosed that improve antimicrobial activity, enhance the durability of antimicrobial action against selection or induction of resistance, and provide two synergistic mechani...  
WO/2021/202208A1
Embodiments of methods are disclosed for inhibiting, regulating and/or otherwise affecting or managing the pri-miR- 17-92 cluster, and certain pre-miRNA's embedded in the cluster as well as the pre-miRNA's themselves as isolated forms, a...  
WO/2021/202621A2
The present disclosure relates to compounds useful for the detection or modulation of target nucleic acids, including DNA and RNA. The present disclosure further relates to methods for treatment of trinucleotide repeat disorders, which c...  
WO/2021/179081A1
The present document describes methods of using a gem-difluorinated C-glycopeptide compound of general formula I, or a pharmaceutically acceptable base, addition salt with an acid, hydrate or solvate of the compound of general formula I ...  
WO/2021/153687A1
Disclosed is a nucleic acid complex represented by formula (I) or a pharmaceutically acceptable salt thereof (X is CH2 or O; Y is a sugar ligand having mannose or GalNac; n is an integer of 1 to 8; and Z is a group containing an oligonuc...  
WO/2021/146812A1
The present document describes uses and methods of using a gem-difluorinated C-glycopeptide compound of general formula I, or a pharmaceutically acceptable base, addition salt with an acid, hydrate or solvate of the compound of general f...  
WO/2021/084552A1
The present invention relates to liposomally bound novel peptide fragments complexed with one or more TLR1/2 and TLR9 ligands useful as vaccine against tuberculosis and for enhancing BCG vaccine efficacy upon concomitant use.  
WO/2021/081420A2
Provided herein are certain nucleic acids (e.g., double stranded siRNA molecules), as well as conjugates that comprise a targeting moiety, a double stranded siRNA, and optional linking groups. Certain embodiments also provide synthetic m...  
WO/2021/068080A1
Described herein is an immunogenic fusion protein comprising: an immunogenic peptide or an immunogenic variant thereof, the immunogenic peptide comprising the following motifs: - KQPAa; QPAKa; PAKQa; or AKQPa; - NPDPb; PNPDb; DPNPb; or P...  
WO/2021/067741A1
The present disclosure describes a CD4+ T cell repertoire that recognizes a glycopeptide epitope on gp120 presented by a MHCII pathway. The present disclosure provides gp120 glycopeptides that are capable of inducing specific humoral and...  
WO/2021/056098A1
Neoglycoconjugates as immunogens and therapeutic/diagnostic tools are described herein. The neoglycoconjugates are produced by conjugating a carbohydrate antigen intermediate to a free amine group of a carrier material (e.g., carrier pro...  
WO/2021/060980A1
Provided herein are lipidated glycopeptide compounds of formula (I); or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof. R1 is a lipid, R2 is -H or a lipid, and R3 and R4 are as defined herein. These compoun...  
WO/2021/046139A1
Methods for analysis of a glucuronide ligand-drug conjugate are provided.  
WO/2020/229982A1
The present disclosure provides antibody drug conjugates comprising STING modulators. Also provided are compositions comprising the antibody drug conjugates. The compounds and compositions are useful for stimulating an immune response in...  
WO/2020/222100A1
Method for purifying at least one lipoglycopeptide antibiotic comprising the steps of: i) dissolving said at least one lipoglycopeptide antibiotic in an aqueous solution to form a mixture, ii) loading said mixture into a chromatographic ...  
WO/2020/182203A1
Disclosed is a separation and purification method for a vancomycin analogue (I). The method comprises: using a vancomycin crude product as a raw material, firstly using polymer matrix chromatography packing for enrichment, and then perfo...  
WO/2020/176921A1
The present disclosure relates to glycoprotein CD52 and fusion proteins thereof, wherein the CD52 glycoprotein has α-2,3-sialylated N-glycans, O-glycosylation and a pI of about 5 to about 6. The disclosure further relates to the prepara...  
WO/2020/159389A1
The subject of the invention comprises new compounds forming Van-TPlO conjugates, method of their preparation, composition and use in antibacterial treatment against Staphylococcus aureus, Enterococcus spp. and Neisseria spp.  
WO/2020/150394A1
IL-17-producing γδ T cells and CD4+ TH17 cells were identified in fibrotic tissue surrounding human breast implants. In both murine and human tissue samples, senescent cells developed around the implants, which was linked to the IL-17 ...  
WO/2020/124032A1
Described herein are peptides and variants thereof as well as peptide constructs comprising peptides conjugated to, linked to, or fused to agents, wherein the peptides and peptide constructs are capable of binding TfR. Binding of a pepti...  
WO/2020/060491A1
The invention relates to a compound of formula la and/or formula lb: or a pharmaceutically acceptable salt, solvate or prodrug thereof, where the groups are defined herein. The invention also relates to a pharmaceutical formulation compr...  
WO/2020/057422A1
A vancomycin derivative represented by general formula (I) and a pharmaceutically acceptable salt thereof, a preparation method for the vancomycin derivative, and uses of these compounds in preparation of medicaments for treating and/or ...  
WO/2020/016855A1
Aberrant cross talk between Notch ligand (e.g. Jagl) and Notch receptor (e.g. Notch 1) has been implicated in tumorigenesis in the colon. Inhibition of Notch pathway is therefore an attractive approach for treating diseases with upregula...  
WO/2019/227163A1
The present invention relates to peptides with alternating stereochemistry. In particular, the invention relates to peptides comprising alternating stereochemistry of (LDLD) in the first four amino acid residues. The invention further co...  
WO/2019/170046A1
Disclosed are glycopeptide compounds having activity of resisting drug-resistant bacteria, conforming to glycopeptide compounds represented by general formula (I). The present invention also provides a preparation method for and an appli...  
WO/2019/157233A1
Disclosed herein are compositions for assessing peptidoglycan (PG) biosynthesis in bacteria using modified D-amino acids covalently attached to a molecular rotor and visualizing the labeled PG in bacteria based upon the enhanced fluoresc...  
WO/2019/122327A1
The present invention relates to a newly identified bio-surfactant producing bacterial strain, Bacillus subtilis QVS1, which was deposited under accession number LMG P-30406, and to fermentative processes wherein such a strain is employe...  
WO/2019/122234A1
The present invention relates to recombinant polypeptide therapeutics having an engineered O-linked amino acid (AA) glycosylation sequence (motif), which is covalently linked to O-glycan(s) (tag). Recombinant O-glycosylated polypeptides ...  
WO/2019/096234A1
As represented by formula I, a glycopeptide antibiotic compound having anti-drug-resistant bacteria activity or a pharmaceutically acceptable salt of same, a pharmaceutical preparation of same, a preparation method for same, and applicat...  
WO/2018/217800A1
Provided herein are methods and compositions for the treatment of Gram positive bacterial infections. The infection in some embodiments, is a pulmonary infection. The method for treating the bacterial infection, comprises in one embodime...  
WO/2018/209223A1
The present disclosure relates to the identification and application of adaptive immune receptor sequences that indicate an elevated risk of developing an adaptive immune receptor-related disease, such as an autoimmune disease (e.g., mul...  
WO/2018/190776A1
The present invention provides compounds of formula (I), polymers and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising said compounds, methods of preparing said compounds or pharmaceutical compositions, a...  
WO/2018/150196A1
The present invention relates to peptides, in particular cell penetrating peptides, of 40 amino acid residues or less comprising at least one directly glycosylated amino acid residue and one or more arginine rich arm domains, and to conj...  
WO/2018/129328A1
Compositions and methods for optically-verified, sequence-controlled polymer synthesis are described.  
WO/2018/102889A1
A construct comprising: (i) an optionally derivatized glycopeptide antibiotic; (ii) a nanoparticle; and (iii) a first linker connecting (i) and (ii) is provided. The construct may further comprise a second linker located between the firs...  
WO/2018/102890A1
A visualization construct comprising: (i) an optionally derivatized glycopeptide antibiotic; (ii) a visualization component; and (iii) a first linker connecting (i) and (ii) is provided. The visualization component may be a fluorescent c...  
WO/2018/089858A1
The disclosed embodiments concern methods, devices, and systems for identifying candidate biomarkers useful for the diagnosis, prognosis, monitoring and screening and/or as targets for the treatment of diseases and conditions in subjects...  
WO/2018/051291A1
The present technology relates to vaccine compositions comprising at least one of the nine peptides defined by SEQ ID NO 1-9, capable of stimulating the development of a T helper 1 (Th1)-type cell immune response with high production of ...  
WO/2018/045889A1
Provided are a crystal form A of oritavancin diphosphate, and a preparation method and use thereof. The crystal form has excellent properties in the aspects of dissolution time, biological release, chemical stability, and processing adap...  
WO/2018/037343A1
The present technology relates to vaccine compositions for the treatment and/or prevention of visceral leishmaniasis in mammals, comprising six synthetic peptides that are free or expressed in the surface of non-infectious bacteriophages...  
WO/2018/031887A1
Methods and assays for detecting natalizumab in a sample, natalizumab-peptide complexes in a sample, and point-of-care devices for detecting natalizumab in a sample are described herein.  

Matches 1 - 50 out of 1,182